Well, like clockwork, Genentech has released the quarterly fatalities report for Hemlibra.(Emicizumab)
Dr. Aledort stated that " It is understandable that both patients with hemophilia A and their physicians are enthusiastic about the potential advantages of subcutaneous administration of emicizumab. However, I am concerned that we may be seeing the beginning of a serious public health issue. This population of patients has already been exposed to risks associated with therapy, and we should embrace this very important biologic agent with caution. "
We will be following up next quarter on the next fatalities report. The number will mostly likely be over 30. Anyone wanna start placing bets?